300 related articles for article (PubMed ID: 22580742)
1. Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?
Barnum CJ; Tansey MG
Curr Neurol Neurosci Rep; 2012 Aug; 12(4):350-8. PubMed ID: 22580742
[TBL] [Abstract][Full Text] [Related]
2. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Hirsch EC; Hunot S
Lancet Neurol; 2009 Apr; 8(4):382-97. PubMed ID: 19296921
[TBL] [Abstract][Full Text] [Related]
3. Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.
Knaryan VH; Samantaray S; Le Gal C; Ray SK; Banik NL
J Neurochem; 2011 Aug; 118(3):326-38. PubMed ID: 21615738
[TBL] [Abstract][Full Text] [Related]
4. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
Vivekanantham S; Shah S; Dewji R; Dewji A; Khatri C; Ologunde R
Int J Neurosci; 2015; 125(10):717-25. PubMed ID: 25364880
[TBL] [Abstract][Full Text] [Related]
5. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
[TBL] [Abstract][Full Text] [Related]
6. Circadian rhythms, Neuroinflammation and Oxidative Stress in the Story of Parkinson's Disease.
Vallée A; Lecarpentier Y; Guillevin R; Vallée JN
Cells; 2020 Jan; 9(2):. PubMed ID: 32012898
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease: clinical aspects.
Klockgether T
Cell Tissue Res; 2004 Oct; 318(1):115-20. PubMed ID: 15365814
[TBL] [Abstract][Full Text] [Related]
8. When does Parkinson's disease begin? From prodromal disease to motor signs.
Meissner WG
Rev Neurol (Paris); 2012 Nov; 168(11):809-14. PubMed ID: 22981298
[TBL] [Abstract][Full Text] [Related]
9. Is Braak staging valid for all types of Parkinson's disease?
Jellinger KA
J Neural Transm (Vienna); 2019 Apr; 126(4):423-431. PubMed ID: 29943229
[TBL] [Abstract][Full Text] [Related]
10. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.
Gerlach M; Riederer P
J Neural Transm (Vienna); 1996; 103(8-9):987-1041. PubMed ID: 9013391
[TBL] [Abstract][Full Text] [Related]
11. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
12. Modeling neuroinflammatory pathogenesis of Parkinson's disease.
Barnum CJ; Tansey MG
Prog Brain Res; 2010; 184():113-32. PubMed ID: 20887872
[TBL] [Abstract][Full Text] [Related]
13. l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
Del-Bel E; Bortolanza M; Dos-Santos-Pereira M; Bariotto K; Raisman-Vozari R
Synapse; 2016 Dec; 70(12):479-500. PubMed ID: 27618286
[TBL] [Abstract][Full Text] [Related]
14. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
[TBL] [Abstract][Full Text] [Related]
15. Nigral degeneration in Parkinson's disease.
Rinne JO
Mov Disord; 1993; 8 Suppl 1():S31-5. PubMed ID: 8302305
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and infection in Parkinson's disease.
Arai H; Furuya T; Mizuno Y; Mochizuki H
Histol Histopathol; 2006 Jun; 21(6):673-8. PubMed ID: 16528677
[TBL] [Abstract][Full Text] [Related]
17. Neuroinflammation in Parkinson's disease.
Hirsch EC; Vyas S; Hunot S
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S210-2. PubMed ID: 22166438
[TBL] [Abstract][Full Text] [Related]
18. Sex-specific neuroprotection by inhibition of the Y-chromosome gene,
Lee J; Pinares-Garcia P; Loke H; Ham S; Vilain E; Harley VR
Proc Natl Acad Sci U S A; 2019 Aug; 116(33):16577-16582. PubMed ID: 31371505
[TBL] [Abstract][Full Text] [Related]
19. Hyper-serotonergic state determines onset and progression of idiopathic Parkinson's disease.
da Cruz Moreira-Junior E
Med Hypotheses; 2019 Dec; 133():109399. PubMed ID: 31542611
[TBL] [Abstract][Full Text] [Related]
20. The role of glial reaction and inflammation in Parkinson's disease.
Hirsch EC; Breidert T; Rousselet E; Hunot S; Hartmann A; Michel PP
Ann N Y Acad Sci; 2003 Jun; 991():214-28. PubMed ID: 12846989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
